Breaking News Instant updates and real-time market news.

2022-01-27 06:52:54 LUV Southwest $43.68 / -0.17 (-0.39%) 06:52 01/27/22 01/27 06:52 01/27/22 06:52	Southwest says reducing Q1 capacity The company said, "Based on current cost trends and recently reduced capacity plans, first quarter 2022 operating expenses, excluding fuel and oil expense, special items, and profitsharing, are expected to increase in the range of 20 percent to 24 percent on a unit basis5 as compared with first quarter 2019, an increase from the Company's previous guidance of 10 percent to 14 percent. The Company continues to experience cost pressure due to inflation in labor rates and airport costs, as well as unit cost headwinds from operating at suboptimal productivity levels. Additionally, the Company has temporarily extended incentive pay to its Operations Employees through early February 2022, which is expected to result in an additional $150 million of salaries, wages, and benefits expense in first quarter 2022. Furthermore, the Company is reducing its first quarter 2022 capacity to provide additional stability during this challenging environment. Compared with the Company's previous first quarter 2022 unit cost guidance, excluding fuel and oil expense, special items, and profitsharing, approximately half of the estimated unit cost increase is attributable to the temporary incentive pay offered to Operations Employees, and the remaining half is driven by reduced capacity. The Company now expects its first quarter and full year 2022 interest expense to be $90 million and $360 million, respectively, a decrease from its previous expectation of $110 million and $440 million, respectively, due to the Company's adoption of a new accounting standard related to convertible debt. Effective January 1, 2022, the Company adopted Accounting Standards Update (ASU) No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. As a result of this new standard, the Company will no longer record amortization of the debt discount associated with its convertible notes to interest expense."	27 Jan 27 Jan

2022-01-27 06:52:54

LUV

Southwest

$43.68 / -0.17 (-0.39%)

06:52

01/27/22

01/27

06:52

01/27/22

06:52

Southwest says reducing Q1 capacity

The company said, "Based on current cost trends and recently reduced capacity plans, first quarter 2022 operating expenses, excluding fuel and oil expense, special items, and profitsharing, are expected to increase in the range of 20 percent to 24 percent on a unit basis5 as compared with first quarter 2019, an increase from the Company's previous guidance of 10 percent to 14 percent. The Company continues to experience cost pressure due to inflation in labor rates and airport costs, as well as unit cost headwinds from operating at suboptimal productivity levels. Additionally, the Company has temporarily extended incentive pay to its Operations Employees through early February 2022, which is expected to result in an additional $150 million of salaries, wages, and benefits expense in first quarter 2022. Furthermore, the Company is reducing its first quarter 2022 capacity to provide additional stability during this challenging environment. Compared with the Company's previous first quarter 2022 unit cost guidance, excluding fuel and oil expense, special items, and profitsharing, approximately half of the estimated unit cost increase is attributable to the temporary incentive pay offered to Operations Employees, and the remaining half is driven by reduced capacity. The Company now expects its first quarter and full year 2022 interest expense to be $90 million and $360 million, respectively, a decrease from its previous expectation of $110 million and $440 million, respectively, due to the Company's adoption of a new accounting standard related to convertible debt. Effective January 1, 2022, the Company adopted Accounting Standards Update (ASU) No. 2020-06, Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. As a result of this new standard, the Company will no longer record amortization of the debt discount associated with its convertible notes to interest expense."

27
Jan
27
Jan

OTHER BREAKING NEWS FROM THE FLY

Hot Stocks	Avis Budget chairman buys $4.9M in common stock » 19:13 05/26/22 05/26 19:13 05/26/22 19:13 CAR Avis Budget $185.03 / +6.06 (+3.39%) In a regulatory filing,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/02/22 Avis Budget jumps 9% to $305.00 after Q1 results beat estimates CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/04/22 Deutsche Bank Avis Budget price target raised to $238 from $193 at Deutsche Bank 04/26/22 Deutsche Bank Hertz named short-term buy idea at Deutsche Bank 04/20/22 Barclays Barclays upgrades Avis to neutral on 'constructive' rental stance 04/20/22 Barclays Avis Budget upgraded to Equal Weight from Underweight at Barclays CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/02/22 Avis Budget reports Q1 adjusted EPS $9.99, consensus $3.45 02/14/22 Avis Budget reports Q4 adjusted EPS $7.08, consensus $6.15 CAR Avis Budget $185.03 / +6.06 (+3.39%) 02/24/22 Car rental companies expect shortages to continue, WSJ reports CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/03/22 Fly Intel: Pre-market Movers 05/02/22 Fly Intel: After-Hours Movers 04/20/22 What You Missed On Wall Street On Wednesday 04/20/22 What You Missed On Wall Street This Morning CAR Avis Budget $185.03 / +6.06 (+3.39%) 05/20/22 Avis Budget put volume heavy and directionally bearish 05/02/22 Avis Budget options imply 15.7% move in share price post-earnings 02/14/22 Avis Budget options imply 19.8% move in share price post-earnings
Hot Stocks	Myriad Genetics to present multiple genetic studies in cancer treatment at ASCO » 19:04 05/26/22 05/26 19:04 05/26/22 19:04 MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) The company states:… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 05/03/22 Myriad expands partnership with Intermountain Precision Genomics 04/26/22 Myriad Genetics report results on nationwide survey 03/14/22 Myriad Genetics launches Precise Oncology Solutions offering 12/14/21 Myriad Genetics promotes Nicole Lambert to COO MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 10/14/21 Cowen Myriad Genetics coverage transferred at Cowen 06/15/21 Fly Intel: Top five analyst initiations 06/15/21 Raymond James Myriad Genetics initiated with a Market Perform at Raymond James 06/03/21 Goldman Sachs Myriad Genetics initiated with a Sell at Goldman Sachs MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 05/05/22 Myriad Genetics sees 2022 adjusted EPS 0c-20c, consensus 8c 05/05/22 Myriad Genetics reports Q1 adjusted EPS (3c), consensus (7c) 02/24/22 Myriad Genetics sees 2020 adjusted EPS $0-20c, consensus 15c 02/24/22 Myriad Genetics reports Q4 adjusted EPS (2c), consensus (2c) MYGN Myriad Genetics $21.15 / -0.05 (-0.24%) 01/03/22 NY Times investigation finds 85% of positive results from NIPTs are incorrect 06/02/22 Myriad Genetics Inc.
Earnings	Taro Pharmaceutical reports Q4 EPS 73c vs. (78c) last year » 19:01 05/26/22 05/26 19:01 05/26/22 19:01 TARO Taro Pharmaceutical $34.54 / -2.25 (-6.12%) Reports Q4 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research TARO Taro Pharmaceutical $34.54 / -2.25 (-6.12%) 02/22/22 Taro Pharmaceutical to acquire Alchemee, terms undisclosed 12/01/21 Taro Pharmaceutical appoints William Coote CFO TARO Taro Pharmaceutical $34.54 / -2.25 (-6.12%) 01/31/22 H.C. Wainwright Taro Pharmaceutical price target lowered to $73 from $75 at H.C. Wainwright 01/18/22 H.C. Wainwright Taro Pharmaceutical price target lowered to $75 from $82 at H.C. Wainwright 07/28/21 H.C. Wainwright Taro Pharmaceutical price target raised to $82 from $80 at H.C. Wainwright
Hot Stocks	Biomea Fusion to present new preclinical data on BMF-219 at ASCO » 19:00 05/26/22 05/26 19:00 05/26/22 19:00 BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) Biomea Fusion… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 05/19/22 Biomea Fusion announces nomination of BMF-500 as IND candidate 04/08/22 Biomea Fusion: BMF-219 showed strong cytotoxic activity in trial 02/01/22 Biomea Fusion appoints Steve Morris as Chief Medical Officer 01/25/22 Biomea Fusion doses first patient in Phase I trial of BMF-219 BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 05/17/22 Piper Sandler Biomea Fusion price target lowered to $25 from $27 at Piper Sandler 01/12/22 H.C. Wainwright Biomea Fusion initiated with a Buy at H.C. Wainwright 12/16/21 Oppenheimer Biomea Fusion initiated with an Outperform at Oppenheimer BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 05/16/22 Biomea Fusion reports Q1 EPS (56c), consensus (53c) 02/28/22 Biomea Fusion reports Q4 EPS (51c), consensus (45c) 06/13/22 Biomea Fusion 06/22/22 BioMea Fusion, Inc. BMEA Biomea Fusion $5.20 / +0.03 (+0.58%) 03/09/22 Twenty new option listings and one option delisting on March 9th
Recommendations	Equinix price target lowered to $770 from $825 at BMO Capital » 18:57 05/26/22 05/26 18:57 05/26/22 18:57 EQIX Equinix $669.92 / -18.56 (-2.70%) BMO Capital analyst Ari… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options EQIX Equinix $669.92 / -18.56 (-2.70%) 05/19/22 Equinix highlights latest progress on ESG commitments 03/18/22 Equinix to acquire four Entel data centers for $705M 02/24/22 Equinix names Nicole Collins as Chief Transformation Officer 02/07/22 Equinix opens new IBX data center in Aschheim EQIX Equinix $669.92 / -18.56 (-2.70%) 05/24/22 Stifel Equinix added to 'Select List' on selloff at Stifel 04/29/22 JPMorgan Equinix price target raised to $880 from $860 at JPMorgan 04/25/22 Credit Suisse Equinix price target raised to $714 from $673 at Credit Suisse 04/08/22 Deutsche Bank Equinix price target raised to $785 from $780 at Deutsche Bank EQIX Equinix $669.92 / -18.56 (-2.70%) 04/27/22 Equinix sees FY22 revenue $7.29B-$7.34B, consensus $7.24B 04/27/22 Equinix raises FY22 AFFO view to $28.93-$29.26 from $28.87-$29.20 04/27/22 Equinix sees Q2 revenue $1.81B-$1.83B, consensus $1.79B 04/27/22 Equinix reports Q1 adjusted FFO $7.16, consensus $7.19 06/07/22 BMO Hosted Company Meetings at REITweek EQIX Equinix $669.92 / -18.56 (-2.70%) 02/17/22 Early notable gainers among liquid option names on February 17th

Hot Stocks	Mereo BioPharma to present updated Phase 1b/2 data on Etigilimab and Nivolumab » 18:57 05/26/22 05/26 18:57 05/26/22 18:57 MREO Mereo BioPharma / + Mereo BioPharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Events MREO Mereo BioPharma / + 05/17/22 Mereo BioPharma announces appointment of Mullick to board of directors 05/09/22 Mereo BioPharma announces top-line efficacy data from Astraeus Phase 2 trial 04/20/22 Ultragenyx announces first patient dosed in Phase 2/3 study of UX143 03/01/22 Mereo BioPharma announces appointment of Hyland to board of directors 05/31/22 Mereo BioPharma 06/01/22 Mereo BioPharma
Hot Stocks	Affimed to present on three AFM24 clinical trial designs at ASCO 2022 » 18:55 05/26/22 05/26 18:55 05/26/22 18:55 AFMD Affimed $3.15 / -0.02 (-0.63%) Affimed announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly Events AFMD Affimed $3.15 / -0.02 (-0.63%) 05/16/22 Affimed presents data on AFM24, AFM28 in poster presentations 05/12/22 Affimed to present preclinical data on cytotoxic activity of AFM28 04/10/22 Affimed provides data updated from ongoing study of AFM13 Precomplexed with cbNK 04/08/22 Affimed says it reached 'safe and well-tolerated' Phase 2 dose in AFM24 study AFMD Affimed $3.15 / -0.02 (-0.63%) 04/11/22 Cantor Fitzgerald Affimed AFM13 + NK combination data exceed expectations, says Cantor Fitzgerald 03/30/22 Piper Sandler Affimed initiated with an Overweight at Piper Sandler 02/23/22 Cantor Fitzgerald Affimed initiated with an Overweight at Cantor Fitzgerald 02/23/22 Cantor Fitzgerald Affimed initiated with an Overweight at Cantor Fitzgerald 13 Apr AFMD Affimed $3.15 / -0.02 (-0.63%) 04/11/22 What You Missed On Wall Street This Morning 04/11/22 Fly Intel: Pre-market Movers 06/01/22 Affimed - AFMD
Hot Stocks	Oncternal Therapeutics presents interim data for Zilovertamab+Ibrutinib at ASCO » 18:51 05/26/22 05/26 18:51 05/26/22 18:51 ONCT Oncternal Therapeutics / + Oncternal Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ONCT Oncternal Therapeutics / + 04/13/22 Oncternal Therapeutics expects cash runway well into 3Q23 04/13/22 Oncternal Therapeutics deprioritizes development of ONCT-216 01/04/22 Oncternal in pact with FDA for registrational study design for zilovertam in MCL ONCT Oncternal Therapeutics / + 05/10/22 Maxim Oncternal Therapeutics initiated with a Buy at Maxim 02/24/22 BTIG Oncternal Therapeutics initiated with a Buy at BTIG 02/24/22 BTIG Oncternal Therapeutics initiated with a Buy at BTIG ONCT Oncternal Therapeutics / + 05/05/22 Oncternal Therapeutics reports Q1 EPS (20c), consensus (20c) ONCT Oncternal Therapeutics / + 01/05/22 Fly Intel: Pre-market Movers 01/04/22 Fly Intel: After-Hours Movers 06/07/22 2022 ASCO Annual Meeting 06/16/22 Oncternal Therapeutics Inc
Hot Stocks	Puma Biotechnology to present two abstracts on neratinib at ASCO Meeting » 18:49 05/26/22 05/26 18:49 05/26/22 18:49 PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) Puma Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 02/15/22 Coherus Biosciences announces Paul Reider as chief commercial officer 01/12/22 Puma Biotechnology's NERLYNX included in NCCN guidelines for breast cancer 12/10/21 Puma Biotechnology presents updates from Phase II SUMMIT trial PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 05/06/22 H.C. Wainwright Puma Biotechnology price target lowered to $12 from $14 at H.C. Wainwright 09/28/21 Fly Intel: Top five analyst upgrades 09/28/21 Citi Puma Biotechnology upgraded to Buy after 40% selloff at Citi 09/27/21 Citi Puma Biotechnology upgraded to Buy from Neutral at Citi PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 05/05/22 Puma Biotechnology reports Q1 EPS (1c), consensus (17c) 03/03/22 Puma Biotechnology reports Q4 EPS 21c, consensus (9c) PBYI Puma Biotechnology $1.95 / +0.035 (+1.83%) 01/13/22 Fly Intel: Pre-market Movers 06/14/22 Puma Biotechnology, Inc.
Hot Stocks	Invitae to present eight studies at ASCO » 18:48 05/26/22 05/26 18:48 05/26/22 18:48 NVTA Invitae $3.50 / +0.095 (+2.79%) Invitae "announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options NVTA Invitae $3.50 / +0.095 (+2.79%) 05/09/22 NeoGenomics appoints Vishal Sikri as presdent, CCO of Inivata 05/04/22 Cathie Wood's ARK Investment bought 272.5K shares of Invitae today 05/03/22 Allelica enters partnership with Invitae to build ancestry-informed PRS 04/14/22 Invitae falls -7.4% NVTA Invitae $3.50 / +0.095 (+2.79%) 05/04/22 Raymond James Invitae price target lowered to $8.50 from $10.50 at Raymond James 02/28/22 Raymond James Invitae price target lowered to $15 from $36 at Raymond James 11/09/21 Wells Fargo Invitae price target lowered to $25 from $35 at Wells Fargo 10/14/21 Cowen Invitae coverage transferred at Cowen NVTA Invitae $3.50 / +0.095 (+2.79%) 05/03/22 Invitae reports Q1 non-GAAP EPS 78c, consensus (76c) 02/24/22 Invitae sees 2022 revenue $640M, consensus $638.69M 02/24/22 Invitae reports Q4 non-GAAP EPS (81c), consensus (73c) 06/07/22 2022 ASCO Annual Meeting 06/06/22 Invitae Corporation NVTA Invitae $3.50 / +0.095 (+2.79%) 05/03/22 Invitae options imply 14.1% move in share price post-earnings 02/24/22 Invitae options imply 14.1% move in share price post-earnings

Hot Stocks	Arbutus Biopharma to present data from preclinical study of PD-L1 inhibitor » 18:47 05/26/22 05/26 18:47 05/26/22 18:47 ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) Arbutus Biopharma's… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 05/05/22 Arbutus Biopharma expects cash to fund operations into Q2 of 2024 05/05/22 Arbutus Biopharma announces upcoming milestones 02/28/22 Artubus, Genevant file patent infringement suit against Moderna 02/28/22 Genevant Sciences, Arbutus file patent infringement suit against Moderna ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 03/14/22 H.C. Wainwright Arbutus Biopharma price target raised to $8.50 from $8 at H.C. Wainwright 03/04/22 Chardan Arbutus Biopharma price target raised to $6 from $5.50 at Chardan 12/29/21 Jefferies Arbutus Biopharma assumed with a Hold at Jefferies 12/13/21 H.C. Wainwright H.C. Wainwright sees Arbutus' $300M-plus licensing deal for AB-729 as low-risk ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 05/05/22 Arbutus Biopharma reports Q1 EPS (11c), consensus (16c) 03/03/22 Arbutus Biopharma reports 2021 EPS (83c), consensus (86c) ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 05/08/22 Moderna seeks to dismiss COVID vaccine patent lawsuit, WSJ reports ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 12/29/21 Wingstop, Akamai initiations among today's top calls on Wall Street 12/01/21 Wall Street in Fives - Must Read Lists for Wednesday 12/01/21 Wall Street in Fives - Must Read Lists at Midday 10/03/22 6th Annual Genetic Medicines Conference ABUS Arbutus Biopharma $2.31 / +0.055 (+2.44%) 12/02/21 Unusually active option classes on open December 2nd 12/01/21 Unusually active option classes on open December 1st
Hot Stocks	Elevation Oncology to present initial Seribantumab data at ASCO » 18:46 05/26/22 05/26 18:46 05/26/22 18:46 ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) Elevation Oncology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) 05/25/22 Elevation Oncology granted FDA Fast Track designation for seribantumab 04/27/22 Elevation Oncology says initial data from Phase 2 CRESTONE study coming at ASCO 03/14/22 Elevation Oncology names David Dornan, Ph.D., as Chief Scientific Officer ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) 05/06/22 Wedbush Elevation Oncology price target lowered to $15 from $21 at Wedbush 03/04/22 Wedbush Elevation Oncology price target lowered to $21 from $27 at Wedbush 12/23/21 Fly Intel: Top five analyst initiations 12/23/21 H.C. Wainwright Elevation Oncology initiated with a Buy at H.C. Wainwright ELEV Elevation Oncology $3.35 / -0.62 (-15.64%) 05/05/22 Elevation Oncology reports Q1 EPS (74c), consensus (50c) 03/03/22 Elevation Oncology reports Q4 EPS ($2.64), consensus (59c) 25 Jun 06/07/22 2022 ASCO Annual Meeting 06/17/22 Elevation Oncology, Inc.
Hot Stocks	PDS Biotechnology announces presentation of Phase 2 data on PDS0101 at ASCO » 18:42 05/26/22 05/26 18:42 05/26/22 18:42 PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) PDS Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/18/22 PDS Biotechnology appoints Sanjay Zaveri to SVP, business development 04/19/22 PDS Biotechnology receives $1.2M after selling NOL tax benefits 04/08/22 PDS Biotechnology reports inducement grants under Nasdaq listing rule 03/31/22 PDS Biotechnology expects cash to fund operations through end of 2023 PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/13/22 Alliance Global Partners PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners 10/21/21 H.C. Wainwright H.C. Wainwright says PDS Biotechnology temporary hold shouldn't spark concerns 08/12/21 H.C. Wainwright PDS Biotechnology price target lowered to $15 from $20 at H.C. Wainwright 06/28/21 Cantor Fitzgerald PDS Biotechnology initiated with an Overweight at Cantor Fitzgerald PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/11/22 PDS Biotechnology reports Q1 EPS (32c), consensus (22c) 03/31/22 PDS Biotechnology reports 2021 EPS (66c), consensus (71c) 15 Jun PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 18:31 Today Fly Intel: After-Hours Movers 06/07/22 2022 ASCO Annual Meeting 06/15/22 PDS Biotechnology Corporation
Hot Stocks	Gracell to present updated clinical data on GC012F in multiple myeloma » 18:40 05/26/22 05/26 18:40 05/26/22 18:40 GRCL Gracell $3.00 / -0.045 (-1.48%) Gracell Biotechnologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events GRCL Gracell $3.00 / -0.045 (-1.48%) 05/12/22 Gracell to present clinical data on GC012F in RRMM and B-NHL at EHA2022 04/28/22 Gracell to present longer-term follow-up clinical data evaluating GC012F at ASCO 02/22/22 Gracell reports advancements of TruUCAR CAR-T cell platform 02/17/22 Gracell doses first patients in clinical trial of lymphoma candidate GC012F GRCL Gracell $3.00 / -0.045 (-1.48%) 04/04/22 BTIG BTIG starts Gracell at Buy, sees stock trading at 'significant discount' 04/04/22 BTIG Gracell initiated with a Buy at BTIG 03/14/22 Piper Sandler Gracell price target lowered to $25 from $40 at Piper Sandler 06/14/21 Piper Sandler Gracell plans to expand GC012F's clinical profile, says Piper Sandler GRCL Gracell $3.00 / -0.045 (-1.48%) 05/16/22 Gracell reports Q1 EPS (RMB0.33) vs. (RMB0.47) last year 03/14/22 Gracell reports Q4 EPS (6c), one estimate (33c) GRCL Gracell $3.00 / -0.045 (-1.48%) 04/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/14/22 Fly Intel: Pre-market Movers 06/01/22 China Biotech Day 06/07/22 2022 ASCO Annual Meeting 06/11/22 EHA 2022
Hot Stocks	SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO » 18:39 05/26/22 05/26 18:39 05/26/22 18:39 SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) , GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) SpringWorks Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/24/22 SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial 04/19/22 SpringsWorks announces agreeement with Regeneron for nirogacestat 12/10/21 SpringsWorks Therapeutics announces trial collaboration with AbbVie 12/06/21 SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 04/29/22 SK bioscience, GSK report COVID-19 vaccine candidate meets Phase 3 objectives 04/27/22 GSK expects COVID-19 solutions to contribute similar sales level to 2021 04/27/22 GlaxoSmithKline sees FY Specialty Medicines sales up 10% at CER 04/27/22 GlaxoSmithKline CEO says delivered 'strong' Q1 results SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/24/22 Goldman Sachs SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs 03/01/22 H.C. Wainwright SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright 10/27/21 Wedbush Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data 09/08/21 JPMorgan SpringsWorks price target raised to $105 from $97 at JPMorgan GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 05/19/22 Deutsche Bank GlaxoSmithKline price target raised to 1,750 GBp at Deutsche Bank 05/17/22 Roth Capital Ideaya Biosciences price target raised to $46 from $42 at Roth Capital 05/13/22 Jefferies Roche downgraded to Hold from Buy at Jefferies 04/29/22 Barclays GlaxoSmithKline price target raised to 1,800 GBp from 1,775 GBp at Barclays SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/05/22 SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02) 02/24/22 SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c) GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 04/27/22 GlaxoSmithKline reaffirms FY22 sales growth between 5%-7% at CER 04/27/22 GlaxoSmithKline reports Q1 adjusted EPS 32.8p vs. 22.9p last year 04/13/22 GlaxoSmithKline backs FY22 revenue view up 5%-7% at CER, consensus $47.34B 02/25/22 Vir Biotechnology falls 5% after Q4 sales top estimates GSK GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 05/25/22 Nestle mulled GSK consumer deal, but dropped idea, Bloomberg reports 05/25/22 Nestle considered GSK consumer deal, but dropped idea, Bloomberg says 03/30/22 DOJ probes network accused of selling counterfeit HIV drugs, WSJ reports 02/06/22 Two big Unilever investors want split or new chair, FT reports SWTX GSK SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 18:31 Today Fly Intel: After-Hours Movers 05/24/22 What You Missed On Wall Street On Tuesday 05/24/22 What You Missed On Wall Street This Morning 05/13/22 Proven algorithm says sell these stocks now GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 04/13/22 What You Missed On Wall Street On Wednesday 04/13/22 What You Missed On Wall Street This Morning 04/13/22 Fly Intel: Pre-market Movers 01/31/22 Meet Lyell: Fly exclusive interview with CEO Liz Homans 06/07/22 2022 ASCO Annual Meeting GSK GSK GlaxoSmithKline $44.41 / -0.57 (-1.27%) 05/09/22 GlaxoSmithKline call volume above normal and directionally bullish 03/07/22 GlaxoSmithKline put volume heavy and directionally bearish 01/21/22 GlaxoSmithKline call volume above normal and directionally bullish 12/15/21 GlaxoSmithKline call volume above normal and directionally bullish

Hot Stocks	Alaunos Therapeutics to present data on TCR-T Library Phase 1/2 trial » 18:36 05/26/22 05/26 18:36 05/26/22 18:36 TCRT Alaunos Therapeutics / + Alaunos Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options TCRT Alaunos Therapeutics / + 05/16/22 Alaunos Therapeutics expects cash to fund operations into 2Q23 05/02/22 Alaunos Therapeutics doses first patient in TCR-T Library Phase 1/2 trial 03/30/22 Alaunos Therapeutics expects cash to fund operations into 2Q23 01/26/22 Ziopharm highlights operational updates, rebrands to Alaunos Therapeutics TCRT Alaunos Therapeutics / + 05/04/22 Wells Fargo Wells Fargo upgrades Alaunos Therapeutics to Overweight with $3 price target 05/04/22 Wells Fargo Alaunos upgraded to Overweight from Equal Weight at Wells Fargo TCRT Alaunos Therapeutics / + 05/16/22 Alaunos Therapeutics reports Q1 EPS (5c), consensus (7c) 03/30/22 Alaunos Therapeutics reports Q4 EPS (5c), consensus (8c) 06/13/22 Alaunos Therapeutics Inc TCRT Alaunos Therapeutics / + 03/09/22 ZIOPHARM Oncology Inc. options imply 13.4% move in share price post-earnings 01/27/22 One new option listing and one option delisting on January 27th
Earnings	Loop Industries reports FY22 EPS (99c), consensus (88c) » 18:36 05/26/22 05/26 18:36 05/26/22 18:36 LOOP Loop Industries $5.53 / +0.04 (+0.73%) Daniel Solomita, Founder… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Options LOOP Loop Industries $5.53 / +0.04 (+0.73%) 05/16/22 Loop Industries enters commercial supply agreement with Danone 05/16/22 Loop Industries enters multi-year supply agreement with Danone LOOP Loop Industries $5.53 / +0.04 (+0.73%) 10/28/21 Raymond James Loop Industries initiated with an Outperform at Raymond James 10/07/21 H.C. Wainwright Loop Industries upgraded to Buy from Neutral at H.C. Wainwright LOOP Loop Industries $5.53 / +0.04 (+0.73%) 01/11/22 Loop Industries options imply 5.3% move in share price post-earnings
Hot Stocks	Xencor reports initial dose-escalation Phase 1 data of XmAb 104 » 18:32 05/26/22 05/26 18:32 05/26/22 18:32 XNCR Xencor $22.36 / +0.03 (+0.13%) Xencor reported initial… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events XNCR Xencor $22.36 / +0.03 (+0.13%) 05/05/22 Xencor to end 2022 with $500M-$550M in cash 04/08/22 Xencor presents data from multiple preclinical XmAb cytokine programs at AACR 02/23/22 Xencor sees ending 2021 with $500M-$550M in cash, cash equivalents 12/12/21 Xencor presents data from Phase 1 dose-escalation study of plamotamab XNCR Xencor $22.36 / +0.03 (+0.13%) 05/23/22 Piper Sandler Xencor price target lowered to $42 from $66 at Piper Sandler 05/06/22 Piper Sandler Xencor price target lowered to $66 from $71 at Piper Sandler 02/24/22 H.C. Wainwright Xencor price target lowered to $55 from $61 at H.C. Wainwright 02/10/22 BMO Capital Xencor initiated with an Outperform at BMO Capital XNCR Xencor $22.36 / +0.03 (+0.13%) 05/05/22 Xencor reports Q1 EPS 39c, consensus (60c) 02/23/22 Xencor reports Q4 EPS $1.21, consensus (10c) 06/23/22 Xencor, Inc.
On The Fly	Fly Intel: After-Hours Movers » 18:31 05/26/22 05/26 18:31 05/26/22 18:31 RRGB Red Robin $8.61 / +0.6 (+7.49%) , ULTA Ulta Beauty $378.10 / +25.03 (+7.09%) , DELL Dell Technologies $44.00 / +0.705 (+1.63%) , MRVL Marvell $56.90 / +2.93 (+5.43%) , ADSK Autodesk $191.37 / +4.92 (+2.64%) , ACET Adicet Bio $10.23 / +0.04 (+0.39%) , PMVP PMV Pharmaceuticals $13.21 / +0.125 (+0.96%) , ZYME Zymeworks $6.35 / +0.44 (+7.45%) , PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) , GPS Gap $11.15 / +0.5 (+4.69%) , AEO American Eagle $13.99 / +0.425 (+3.13%) , WDAY Workday $168.04 / +3.57 (+2.17%) , COST Costco $465.33 / +25.32 (+5.75%) , IOVA Iovance Biotherapeutics $15.11 / +0.325 (+2.20%) , SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) , MRTX Mirati Therapeutics $58.42 / +0.43 (+0.74%) … Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RRGB ULTA DELL MRVL ADSK ACET PMVP ZYME PDSB GPS AEO WDAY COST IOVA SWTX MRTX RRGB Red Robin $8.61 / +0.6 (+7.49%) 16:35 Today Red Robin jumps 13% to $9.76 after Q1 earnings beat 16:15 Today Red Robin backs FY22 adjusted EBITDA view of $90M-$90M 03/10/22 Red Robin sees FY22 adjusted EBITDA $80M-$90M ULTA Ulta Beauty $378.10 / +25.03 (+7.09%) 16:33 Today Ulta Beauty jumps 7.6% to $406.50 after Q1 earnings beat and guidance raise 16:33 Today Ulta Beauty jumps 7.6% to $406.50 after Q1 earnings beat and guidance raise 05/19/22 Ulta Beauty launches retail media network UB Media 03/28/22 PayPal broadens access to post purchase services for merchants DELL Dell Technologies $44.00 / +0.705 (+1.63%) 16:30 Today Dell Technologies jumps 7% to $47.02 after Q1 results beat estimates 16:28 Today Dell Technologies ended Q1 with performance obligations of $42B 16:27 Today Dell Technologies co-COO calls Q1 a 'record first quarter' 05/23/22 T-Mobile, Dell Technologies partner for 5G connectivity, edge compute MRVL Marvell $56.90 / +2.93 (+5.43%) 05/09/22 Marvell to acquire Tanzanite in an all-cash transaction 04/20/22 Marvell appoints Sara Andrews to board of directors 04/14/22 Worldwide semiconductor revenue grew 26% in 2021, Gartner says 03/14/22 Marvell CEO: The company is performing extremely well ADSK Autodesk $191.37 / +4.92 (+2.64%) 03/24/22 Autodesk to acquire The Wild, terms not disclosed 01/19/22 Autodesk acquires Moxion cloud solution 01/06/22 Autodesk names Rebecca Pearce Chief People Officer 12/16/21 Autodesk to acquire ProEst, terms not disclosed ACET Adicet Bio $10.23 / +0.04 (+0.39%) 18:10 Today Adicet Bio's ADI-001 shows 67% response rate for NHL in Phase 1 trial 04/19/22 Adicet Bio gets FDA fast track designation for lead candidate ADI-001 12/06/21 Adicet Bio trading resumes 12/06/21 Adicet Bio trading halted, volatility trading pause PMVP PMV Pharmaceuticals $13.21 / +0.125 (+0.96%) 17:34 Today PMV Pharmaceuticals: Lead program, PC14586 accepted as oral presentation at ASCO 04/27/22 PMV Pharmaceuticals to present initial PC14586 Phase 1 data at ASCO ZYME Zymeworks $6.35 / +0.44 (+7.45%) 17:42 Today Zymeworks to present zanidatamab antibody data at ASCO 05/20/22 Zymeworks rejects unsolicited acquisition proposal from All Blue Falcons FZE 05/04/22 Zymeworks expects cash to fund operations into second half of 2023 04/29/22 Zymeworks rises 31.7% PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/18/22 PDS Biotechnology appoints Sanjay Zaveri to SVP, business development 04/19/22 PDS Biotechnology receives $1.2M after selling NOL tax benefits 04/08/22 PDS Biotechnology reports inducement grants under Nasdaq listing rule 03/31/22 PDS Biotechnology expects cash to fund operations through end of 2023 GPS Gap $11.15 / +0.5 (+4.69%) 16:23 Today Gap falls 14% to $9.60 after Q1 earnings miss and guidance cut 16:17 Today Gap reports Q1 SSS down 14% y/y 04/22/22 Gap falls -17.9% 04/22/22 Gap falls -22.2% AEO American Eagle $13.99 / +0.425 (+3.13%) 16:24 Today American Eagle down 4% to $13.50 after lowering outlook for year 16:19 Today American Eagle CEO says committed to 'right-setting the business' 03/02/22 American Eagle says 'taking a cautious view of 2022' 12/29/21 American Eagle completes acquisition of Quiet Logistics WDAY Workday $168.04 / +3.57 (+2.17%) 16:17 Today Workday drops 7% to $155.50 after Q1 EPS misses estimates 05/16/22 Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe 02/28/22 Workday sees FY23 subscription revenue at $5.53B-$5.55B, up 22% y/y 02/14/22 Lone Pine takes stakes in Mastercard, Visa, exits Twitter, Meta Platforms COST Costco $465.33 / +25.32 (+5.75%) 05/04/22 Costco reports April sales of $17.33B, up 13.9% 04/13/22 Costco increases quarterly cash dividend to 90c per share 04/06/22 Costco reports March sales of $21.61B, up 18.7% 03/08/22 Jones Soda's Fountain Syrup now sold at Costco Business Centers IOVA Iovance Biotherapeutics $15.11 / +0.325 (+2.20%) 16:13 Today Iovance announces clinical data for lifileucel in advanced melanoma 04/05/22 Iovance Biotherapeutics provides regulatory update on lifileucel 03/15/22 Iovance Biotherapeutics announces FDA allows IOV-4001 IND to proceed 01/10/22 Iovance appoints Raj Puri as EVP, regulatory strategy, translational medicine SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/24/22 SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial 04/19/22 SpringsWorks announces agreeement with Regeneron for nirogacestat 12/10/21 SpringsWorks Therapeutics announces trial collaboration with AbbVie 12/06/21 SpringsWorks Therapeutics doses first patient in Phase 1b/2 nirogacestat study MRTX Mirati Therapeutics $58.42 / +0.43 (+0.74%) 17:08 Today Mirati Therapeutics says disease control rate was 80% in study 05/19/22 Mirati Therapeutics submits adagrasib MAA to EMA 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 03/21/22 AnaptysBio names Daniel Faga as interim CEO, succeeding Hamza Suria RRGB ULTA DELL MRVL ADSK ACET PMVP ZYME PDSB GPS AEO WDAY COST IOVA SWTX MRTX RRGB Red Robin $8.61 / +0.6 (+7.49%) 04/18/22 Raymond James Red Robin downgraded to Market Perform from Outperform at Raymond James 04/18/22 Raymond James Red Robin downgraded to Market Perform from Outperform at Raymond James 11/23/21 Benchmark Red Robin initiated with a Buy at Benchmark 11/11/21 Raymond James Red Robin price target lowered to $30 from $40 at Raymond James ULTA Ulta Beauty $378.10 / +25.03 (+7.09%) 05/25/22 Deutsche Bank Ulta Beauty price target lowered to $466 from $522 at Deutsche Bank 04/19/22 Piper Sandler Ulta Beauty price target lowered to $465 from $475 at Piper Sandler 04/06/22 Piper Sandler Piper lists winners and losers from semi-annual teen survey 03/16/22 Oppenheimer Estee Lauder price target lowered to $300 from $350 at Oppenheimer DELL Dell Technologies $44.00 / +0.705 (+1.63%) 05/25/22 Evercore ISI Dell Technologies added to 'Tactical Outperform' list at Evercore ISI 05/25/22 JPMorgan Dell Technologies price target lowered to $60 from $68 at JPMorgan 05/23/22 Citi Dell Technologies price target lowered to $65 from $70 at Citi 04/19/22 KGI Securities Dell Technologies initiated with a Neutral at KGI Securities MRVL Marvell $56.90 / +2.93 (+5.43%) 05/25/22 Susquehanna Marvell price target lowered to $90 from $105 at Susquehanna 05/23/22 B. Riley Marvell price target lowered to $72 from $95 at B. Riley 05/23/22 UBS Marvell price target lowered to $80 from $95 at UBS 05/20/22 Oppenheimer Marvell price target lowered to $90 from $110 at Oppenheimer ADSK Autodesk $191.37 / +4.92 (+2.64%) 05/23/22 Stifel Autodesk price target lowered to $230 from $285 at Stifel 05/23/22 RBC Capital Autodesk price target lowered to $255 from $295 at RBC Capital 05/23/22 Deutsche Bank Deutsche Bank downgrades Autodesk on risk to consensus estimates 05/23/22 Deutsche Bank Autodesk downgraded to Hold from Buy at Deutsche Bank ACET Adicet Bio $10.23 / +0.04 (+0.39%) 03/30/22 SMBC Nikko Adicet Bio initiated with an Outperform at SMBC Nikko 03/17/22 JMP Securities Adicet Bio price target lowered to $21 from $30 at JMP Securities 03/08/22 Truist Adicet Bio initiated with a Buy at Truist 03/04/22 Jefferies Adicet Bio initiated with a Buy at Jefferies PMVP PMV Pharmaceuticals $13.21 / +0.125 (+0.96%) 03/02/22 Oppenheimer Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target 03/02/22 Oppenheimer PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer 09/22/21 Goldman Sachs PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs 08/19/21 Oppenheimer PMV Pharmaceuticals initiated with a Perform at Oppenheimer ZYME Zymeworks $6.35 / +0.44 (+7.45%) 05/23/22 H.C. Wainwright Zymeworks price target lowered to $40 from $44 at H.C. Wainwright 05/09/22 Citi Zymeworks should reject 'opportunistic' $10.50 per share offer, says Citi 05/05/22 Guggenheim Zymeworks upgraded to Buy at Guggenheim amid low expectations 05/05/22 Guggenheim Zymeworks upgraded to Buy from Neutral at Guggenheim PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/13/22 Alliance Global Partners PDS Biotechnology price target lowered to $16 from $18 at Alliance Global Partners 10/21/21 H.C. Wainwright H.C. Wainwright says PDS Biotechnology temporary hold shouldn't spark concerns 08/12/21 H.C. Wainwright PDS Biotechnology price target lowered to $15 from $20 at H.C. Wainwright 06/28/21 Cantor Fitzgerald PDS Biotechnology initiated with an Overweight at Cantor Fitzgerald GPS Gap $11.15 / +0.5 (+4.69%) 05/23/22 Citi Gap downgraded to Sell from Neutral at Citi 05/17/22 UBS Gap price target lowered to $14 from $18 at UBS 05/16/22 JPMorgan Gap price target lowered to $11 from $14 at JPMorgan 04/25/22 Guggenheim Guggenheim upgrades Gap to Buy with shares 70% off highs AEO American Eagle $13.99 / +0.425 (+3.13%) 05/23/22 Citi American Eagle downgraded to Neutral from Buy at Citi 05/17/22 B. Riley American Eagle price target lowered to $32 from $41 at B. Riley 05/16/22 JPMorgan American Eagle price target lowered to $20 from $29 at JPMorgan 04/11/22 JPMorgan American Eagle price target lowered to $29 from $32 at JPMorgan WDAY Workday $168.04 / +3.57 (+2.17%) 05/23/22 Cowen Workday price target lowered to $250 from $310 at Cowen 05/20/22 DA Davidson Workday price target lowered to $250 from $300 at DA Davidson 05/20/22 Barclays Workday price target lowered to $238 from $319 at Barclays 05/18/22 Wells Fargo Workday price target lowered to $300 from $340 at Wells Fargo COST Costco $465.33 / +25.32 (+5.75%) 05/25/22 Deutsche Bank Costco price target lowered to $525 from $530 at Deutsche Bank 05/20/22 Oppenheimer Costco price target lowered to $500 from $645 at Oppenheimer 05/19/22 Truist Costco price target lowered to $503 from $634 at Truist 05/19/22 Stifel Costco price target lowered to $515 from $565 at Stifel IOVA Iovance Biotherapeutics $15.11 / +0.325 (+2.20%) 04/07/22 Truist Iovance Biotherapeutics price target lowered to $29 from $32 at Truist 04/07/22 Baird Iovance Biotherapeutics price target raised to $34 from $30 04/06/22 Oppenheimer Iovance 'good news' offset by timeline delay, says Oppenheimer 04/06/22 Goldman Sachs Iovance commentary supports potency assay progress, says Goldman Sachs SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/24/22 Goldman Sachs SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs 03/01/22 H.C. Wainwright SpringsWorks Therapeutics price target raised to $142 from $137 at H.C. Wainwright 10/27/21 Wedbush Wedbush recommends buying SpringsWorks shares ahead of BLENREP combo data 09/08/21 JPMorgan SpringsWorks price target raised to $105 from $97 at JPMorgan MRTX Mirati Therapeutics $58.42 / +0.43 (+0.74%) 05/20/22 Guggenheim Guggenheim upgrades Mirati to Buy on adagrasib's 'highly competitive profile' 05/20/22 Guggenheim Mirati Therapeutics upgraded to Buy from Neutral at Guggenheim 05/05/22 Stifel ASCO sets up as 'downside-biased' for Mirati investors, says Stifel 05/05/22 Citi Mirati Therapeutics price target lowered to $208 from $227 at Citi RRGB ULTA DELL MRVL ADSK ACET PMVP ZYME PDSB GPS AEO WDAY COST IOVA SWTX MRTX RRGB Red Robin $8.61 / +0.6 (+7.49%) 16:14 Today Red Robin reports Q1 EPS (12c), consensus (73c) 03/10/22 Red Robin reports Q4 EPS ($1.36), consensus (53c) ULTA Ulta Beauty $378.10 / +25.03 (+7.09%) 16:07 Today Ulta Beauty raises FY22 EPS view to $19.20-$20.10 from $18.20-$18.70 16:06 Today Ulta Beauty reports Q1 EPS $6.30, consensus $4.46 13:20 Today Notable companies reporting after market close 03/10/22 Ulta Beauty sees FY2 EPS $18.20-$18.70, consensus $17.84 DELL Dell Technologies $44.00 / +0.705 (+1.63%) 16:25 Today Dell Technologies reports Q1 adjusted EPS $1.84, consensus $1.39 13:20 Today Notable companies reporting after market close 02/24/22 Dell Technologies reports Q4 adjusted EPS $1.72, consensus $1.95 02/24/22 Notable companies reporting after market close MRVL Marvell $56.90 / +2.93 (+5.43%) 16:06 Today Marvell sees Q2 adjusted EPS 56c, +/- 3c per share, consensus 55c 16:05 Today Marvell reports Q1 adjusted EPS 52c, consensus 51c 13:20 Today Notable companies reporting after market close 03/03/22 Marvell sees Q1 adjusted EPS 51c +/- 3c, consensus 50c ADSK Autodesk $191.37 / +4.92 (+2.64%) 16:05 Today Autodesk sees FY23 non-GAAP EPS $6.43-$6.66, consensus $6.69 16:04 Today Autodesk sees Q2 non-GAAP EPS $1.54 - $1.60, consensus $1.60 16:03 Today Autodesk reports Q1 non-GAAP EPS $1.43, consensus $1.34 13:20 Today Notable companies reporting after market close ACET Adicet Bio $10.23 / +0.04 (+0.39%) 05/12/22 Adicet Bio reports Q1 EPS (12c), consensus (18c) 03/15/22 Adicet Bio reports Q4 EPS (47c), consensus (42c) PMVP PMV Pharmaceuticals $13.21 / +0.125 (+0.96%) 05/10/22 PMV Pharmaceuticals reports Q1 EPS (41c), consensus (40c) 03/01/22 PMV Pharmaceuticals reports 2021 EPS ($1.28), consensus ($1.22) ZYME Zymeworks $6.35 / +0.44 (+7.45%) 05/04/22 Zymeworks reports Q1 adjusted EPS ($1.17), consensus ($1.67) 02/24/22 Zymeworks reports Q4 EPS (95c), consensus ($1.14) PDSB PDS Biotechnology $4.99 / -0.06 (-1.19%) 05/11/22 PDS Biotechnology reports Q1 EPS (32c), consensus (22c) 03/31/22 PDS Biotechnology reports 2021 EPS (66c), consensus (71c) GPS Gap $11.15 / +0.5 (+4.69%) 16:23 Today Gap cuts FY22 revenue view to down low-mid single digits from low single digits 16:19 Today Gap cuts FY22 EPS view to 30c-60c from $1.85-$2.05 16:17 Today Gap reports Q1 EPS (44c), consensus (13c) 13:20 Today Notable companies reporting after market close AEO American Eagle $13.99 / +0.425 (+3.13%) 16:18 Today American Eagle sees Q2 top-line growth to trend similarly to Q1 16:17 Today American Eagle reports Q1 EPS 16c, consensus 25c 03/02/22 American Eagle reports Q4 adjusted EPS 35c, consensus 35c 03/02/22 Notable companies reporting after market close WDAY Workday $168.04 / +3.57 (+2.17%) 16:04 Today Workday sees Q2 subscription revenue $1.353B-$1.355B 16:02 Today Workday raises FY23 subscription revenue view to $5.537B-$5.557B 16:01 Today Workday reports Q1 EPS 83c, consensus 86c 13:20 Today Notable companies reporting after market close COST Costco $465.33 / +25.32 (+5.75%) 16:20 Today Costco reports Q3 EPS $3.04, consensus $3.03 13:20 Today Notable companies reporting after market close 03/03/22 Costco reports Q2 EPS $2.92, consensus $2.74 03/03/22 Notable companies reporting after market close IOVA Iovance Biotherapeutics $15.11 / +0.325 (+2.20%) 05/05/22 Iovance Biotherapeutics reports Q1 EPS (58c), consensus (64c) SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/05/22 SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02) 02/24/22 SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c) MRTX Mirati Therapeutics $58.42 / +0.43 (+0.74%) 02/28/22 Mirati Therapeutics reports Q4 EPS ($3.72), consensus ($3.00) 02/28/22 Mirati Therapeutics reports Q4 EPS ($3072), consensus ($3.00) 27 Jan 08 Dec 11 Nov 15 Jun DELL PMVP GPS WDAY DELL Dell Technologies $44.00 / +0.705 (+1.63%) 05/22/22 Broadcom in talks to acquire VMware, Reuters reports 01/01/22 Amazon looks particularly attractive after wild year for tech, Barron's says PMVP PMV Pharmaceuticals $13.21 / +0.125 (+0.96%) 05/19/22 Wolfpack issues short report on 'significantly overpriced' PMV 05/19/22 Wolfpack Research announces short position in PMV Pharmaceuticals GPS Gap $11.15 / +0.5 (+4.69%) 04/13/22 Gap highlighted as activist candidate by Activist Insight WDAY Workday $168.04 / +3.57 (+2.17%) 03/05/22 Cloud stocks have become a haven in tech, Barron's says RRGB ULTA DELL MRVL ADSK ACET ZYME GPS AEO WDAY COST IOVA SWTX MRTX RRGB Red Robin $8.61 / +0.6 (+7.49%) 03/10/22 Fly Intel: After-Hours Movers ULTA Ulta Beauty $378.10 / +25.03 (+7.09%) 04/06/22 What You Missed On Wall Street On Wednesday 04/06/22 What You Missed On Wall Street This Morning 03/11/22 What You Missed On Wall Street On Friday 03/11/22 What You Missed On Wall Street This Morning DELL Dell Technologies $44.00 / +0.705 (+1.63%) 04/04/22 Fly Insider: TMC the Metals, Dell among week's notable insider trades 04/01/22 What You Missed On Wall Street On Friday 04/01/22 What You Missed On Wall Street This Morning 04/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations MRVL Marvell $56.90 / +2.93 (+5.43%) 03/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/03/22 Fly Intel: After-Hours Movers 12/03/21 Wall Street in Fives - Must Read Lists for Friday 12/03/21 Wall Street in Fives - Must Read Lists at Midday ADSK Autodesk $191.37 / +4.92 (+2.64%) 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations ACET Adicet Bio $10.23 / +0.04 (+0.39%) 03/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 12/06/21 Wall Street in Fives - Must Read Lists for Monday 12/06/21 Wall Street in Fives - Must Read Lists at Midday ZYME Zymeworks $6.35 / +0.44 (+7.45%) 05/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/29/22 What You Missed On Wall Street On Friday 04/29/22 What You Missed On Wall Street This Morning 04/29/22 Fly Intel: Pre-market Movers GPS Gap $11.15 / +0.5 (+4.69%) 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/25/22 What You Missed On Wall Street On Monday AEO American Eagle $13.99 / +0.425 (+3.13%) 05/23/22 What You Missed On Wall Street On Monday 05/23/22 What You Missed On Wall Street This Morning 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/03/22 What You Missed On Wall Street This Morning WDAY Workday $168.04 / +3.57 (+2.17%) 05/17/22 What You Missed On Wall Street On Tuesday 05/17/22 What You Missed On Wall Street This Morning 05/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/01/22 What You Missed On Wall Street On Tuesday COST Costco $465.33 / +25.32 (+5.75%) 04/07/22 What You Missed On Wall Street On Thursday 04/07/22 What You Missed On Wall Street This Morning 03/04/22 What You Missed On Wall Street On Friday 03/04/22 What You Missed On Wall Street This Morning IOVA Iovance Biotherapeutics $15.11 / +0.325 (+2.20%) 04/05/22 Fly Intel: After-Hours Movers 03/15/22 Fly Intel: After-Hours Movers 01/28/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations SWTX SpringsWorks Therapeutics $30.81 / -1.76 (-5.40%) 05/24/22 What You Missed On Wall Street On Tuesday 05/24/22 What You Missed On Wall Street This Morning 05/13/22 Proven algorithm says sell these stocks now MRTX Mirati Therapeutics $58.42 / +0.43 (+0.74%) 05/20/22 What You Missed On Wall Street This Morning 05/20/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/06/22 Proven algorithm says sell these stocks now 05/27/22 Technology 06/07/22 2022 ASCO Annual Meeting 06/13/22 Semiconductor & Software Bus Tour 16:30 Today Ulta Beauty - ULTA 16:30 Today Workday - WDAY 16:30 Today American Eagle - AEO 16:45 Today Marvell - MRVL 17:00 Today Costco - COST 17:00 Today Autodesk - ADSK 17:00 Today Red Robin - RRGB 17:30 Today Dell Technologies - DELL 18:00 Today Gap - GPS 12/14/22 PDUFA Date for Adagrasib 06/01/22 Ulta Beauty, Inc. 06/02/22 PMV Pharmaceuticals, Inc. 06/02/22 Adicet Bio Inc 06/08/22 American Eagle Outfitters, Inc. 06/10/22 Iovance Biotherapeutics, Inc. 06/15/22 PDS Biotechnology Corporation 06/16/22 Autodesk, Inc. 06/22/22 Workday, Inc. 06/23/22 Marvell Technology Inc 06/27/22 Dell Technologies Inc. CL C ULTA DELL MRVL ADSK GPS AEO WDAY COST IOVA ULTA Ulta Beauty $378.10 / +25.03 (+7.09%) 14:49 Today Ulta Beauty options imply 5.2% move in share price post-earnings 05/09/22 Early notable gainers among liquid option names on May 9th 02/18/22 Early notable gainers among liquid option names on February 18th 12/02/21 Ulta Beauty options imply 6.3% move in share price post-earnings DELL Dell Technologies $44.00 / +0.705 (+1.63%) 15:11 Today Dell Technologies options imply 6.3% move in share price post-earnings MRVL Marvell $56.90 / +2.93 (+5.43%) 13:19 Today Marvell options imply 5.9% move in share price post-earnings 04/28/22 Unusually active option classes on open April 28th 04/07/22 Marvell call buyer realizes 23% same-day gains 04/06/22 Marvell call volume above normal and directionally bullish ADSK Autodesk $191.37 / +4.92 (+2.64%) 15:04 Today Autodesk options imply 6.4% move in share price post-earnings 04/25/22 Unusually active option classes on open April 25th 01/25/22 Autodesk put volume heavy and directionally bearish GPS Gap $11.15 / +0.5 (+4.69%) 13:34 Today Gap options imply 11.2% move in share price post-earnings 05/18/22 Gap put volume heavy and directionally bearish 04/22/22 Gap call volume above normal and directionally bullish 04/13/22 Gap call volume above normal and directionally bullish AEO American Eagle $13.99 / +0.425 (+3.13%) 14:34 Today American Eagle options imply 11.0% move in share price post-earnings 05/19/22 American Eagle call volume above normal and directionally bullish 04/22/22 American Eagle put volume heavy and directionally bearish 04/07/22 American Eagle put volume heavy and directionally bearish WDAY Workday $168.04 / +3.57 (+2.17%) 14:19 Today Workday options imply 7.4% move in share price post-earnings 05/09/22 Workday call volume above normal and directionally bullish 03/25/22 Unusual call flow in option market yesterday 03/24/22 $43M opening trade crossed in Workday tied to hedge COST Costco $465.33 / +25.32 (+5.75%) 13:04 Today Costco options imply 4.9% move in share price post-earnings 05/19/22 Unusually active option classes on open May 19th 05/18/22 Unusually active option classes on open May 18th 04/08/22 Unusually active option classes on open April 8th IOVA Iovance Biotherapeutics $15.11 / +0.325 (+2.20%) 05/05/22 Iovance Biotherapeutics options imply 9.8% move in share price post-earnings 04/29/22 Iovance Biotherapeutics call volume above normal and directionally bullish 04/06/22 Unusually active option classes on open April 6th
Hot Stocks	Spectrum to present data on poziotinib in NSCLC at ASCO Meeting » 18:28 05/26/22 05/26 18:28 05/26/22 18:28 SPPI Spectrum / + Spectrum Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events Options SPPI Spectrum / + 05/11/22 Spectrum names Nora Brennan as CFO 04/11/22 Spectrum announces resubmitted eflapegrastim BLA accepted for filing 03/07/22 Spectrum reports 'positive' data for poziotinib in ZENITH20 clinical trial 02/11/22 Spectrum announces poziotinib NDA accepted for review by FDA SPPI Spectrum / + 03/21/22 B. Riley Spectrum price target lowered to $4 from $6 at B. Riley 08/18/21 B. Riley Spectrum price target lowered to $6 from $8 at B. Riley 06/01/21 H.C. Wainwright H.C. Wainwright remains bullish on Spectrum as FDA inspects Rolontis facility SPPI Spectrum / + 03/17/22 Spectrum Pharmaceuticals reports Q4 adjusted EPS (17c), consensus (21c) SPPI Spectrum / + 12/02/21 Spectrum could be 'undervalued' if poziotinib hits in NSCLC, Dealreporter says 09/09/22 PDUFA Date for 11/24/22 PDUFA Date for Poziotinib 06/21/22 Spectrum Pharmaceuticals SPPI Spectrum / + 03/17/22 Spectrum options imply 19.8% move in share price post-earnings 03/07/22 Spectrum options imply 14.4% move in share price post-earnings

Hot Stocks	Amgen to present new data from oncology pipeline at ASCO » 18:26 05/26/22 05/26 18:26 05/26/22 18:26 AMGN Amgen $253.01 / +0.05 (+0.02%) , TAK Takeda Pharmaceutical $14.84 / -0.06 (-0.40%) Results From the PARADIGM… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options AMGN TAK AMGN Amgen $253.01 / +0.05 (+0.02%) 05/16/22 Crispr Therapeutics appoints Morrow as CMO 05/04/22 BeiGene granted conditional approval of Blincyto by China NMPA 04/27/22 Amgen receives notice of deficiency from IRS for 2013-2015 period 04/27/22 Amgen's reports safety and efficacy results of Repatha Phase 3 studies TAK Takeda Pharmaceutical $14.84 / -0.06 (-0.40%) 05/16/22 Mirati Therapeutics appoints Laurie Stelzer as CFO 04/28/22 Centogene expands partnership with Takeda Pharmaceutical 04/19/22 Takeda Pharmaceutical receives approval from Japan MHLW for Nuvaxovid 04/12/22 Takeda Pharmaceutical announces SHP643-301 study meets objectives AMGN TAK AMGN Amgen $253.01 / +0.05 (+0.02%) 05/23/22 SVB Leerink Radius Health initiated with a Market Perform at SVB Leerink 05/23/22 SVB Leerink Amgen initiated with a Market Perform at SVB Leerink 05/10/22 Mizuho Amgen price target raised to $208 from $202 at Mizuho 05/05/22 Stifel ASCO sets up as 'downside-biased' for Mirati investors, says Stifel TAK Takeda Pharmaceutical $14.84 / -0.06 (-0.40%) 05/13/22 BTIG Poseida Therapeutics price target lowered to $20 from $40 at BTIG 03/31/22 Canaccord Canaccord starts Morphic at Buy, sees potential to take share from Takeda 02/11/22 BTIG Protagonist Therapeutics initiated with a Buy at BTIG 02/11/22 BTIG Morphic initiated with a Buy at BTIG AMGN AMGN Amgen $253.01 / +0.05 (+0.02%) 04/27/22 Amgen backs FY22 adjusted EPS view $17.00-$18.00, consensus $17.63 04/27/22 Amgen reports Q1 adjusted EPS $4.25, consensus $4.10 04/27/22 Notable companies reporting after market close 02/08/22 Amgen sees FY22 revenue $25.4B-$26.5B, consensus $27B AMGN TAK AMGN Amgen $253.01 / +0.05 (+0.02%) 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 12/14/21 Moderna, Amgen among biotech companies pulling out of JPM conference, STAT says TAK Takeda Pharmaceutical $14.84 / -0.06 (-0.40%) 04/18/22 Japan on verge of approving Novavax COVID vaccine, Nikkei reports AMGN TAK AMGN Amgen $253.01 / +0.05 (+0.02%) 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/28/22 What You Missed On Wall Street On Thursday 04/27/22 Fly Intel: After-Hours Movers 02/08/22 Wall Street in Fives - Must Read Lists for Tuesday TAK Takeda Pharmaceutical $14.84 / -0.06 (-0.40%) 01/19/22 Meet Sangamo: Fly exclusive interview with CEO Sandy Macrae, COO Mark McClung 06/07/22 2022 ASCO Annual Meeting 06/21/22 Amgen AMGN AMGN Amgen $253.01 / +0.05 (+0.02%) 02/08/22 Early notable gainers among liquid option names on February 8th 01/03/22 Amgen call volume above normal and directionally bullish
Hot Stocks	Eli Lilly to present data on oncology portfolio » 18:21 05/26/22 05/26 18:21 05/26/22 18:21 LLY Eli Lilly $313.34 / +6.24 (+2.03%) Eli Lilly announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LLY Eli Lilly $313.34 / +6.24 (+2.03%) 05/25/22 Eli Lilly to invest $2.1B in new manufacturing sites in Indiana 05/24/22 Eli Lilly presents data from LUCENT-2 study at DDW 05/20/22 Eli Lilly, Incyte: EMA's CHMP issues positive opinion for OLUMIANT 05/19/22 Eli Lilly's selpercatinib granted FDA orphan designation LLY Eli Lilly $313.34 / +6.24 (+2.03%) 05/23/22 SVB Leerink Eli Lilly initiated with an Outperform at SVB Leerink 05/02/22 Wells Fargo AbbVie price target raised to $200 from $165 at Wells Fargo 05/02/22 Mizuho Eli Lilly price target raised to $356 from $315 at Mizuho 04/29/22 Morgan Stanley Eli Lilly price target raised to $369 from $364 at Morgan Stanley LLY Eli Lilly $313.34 / +6.24 (+2.03%) 04/28/22 Eli Lilly cuts FY22 EPS view to $8.15-$8.30 from $8.50-$8.65, consensus $8.19 04/28/22 Eli Lilly reports Q1 EPS $2.62, consensus $2.14 03/24/22 Erasca reports Q4 EPS ($1.85), consensus (34c) 02/03/22 Eli Lilly backs FY22 EPS view $8.50-$8.65, consensus $7.54 LLY Eli Lilly $313.34 / +6.24 (+2.03%) 03/15/22 Eli Lilly suspends exports of some medicines to Russia, Bloomberg reports 03/07/22 Johnson & Johnson negotiating deals with two Chinese companies, FT reports 02/24/22 Drugmakers criticize Medicare proposal on Biogen's Alzheimer's drug, WSJ says 02/10/22 FDA expresses concerns about quality of China-developed drugs, WSJ reports LLY Eli Lilly $313.34 / +6.24 (+2.03%) 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/28/22 What You Missed On Wall Street On Thursday 04/28/22 What You Missed On Wall Street This Morning 04/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/22 2022 ASCO Annual Meeting 08/04/22 Eli Lilly - LLY 05/31/22 Eli Lilly LLY Eli Lilly $313.34 / +6.24 (+2.03%) 02/18/22 Eli Lilly put volume heavy and directionally bearish 12/15/21 Early notable gainers among liquid option names on December 15th
Hot Stocks	CTI BioPharma to present pivotal data on pacritinib program » 18:19 05/26/22 05/26 18:19 05/26/22 18:19 CTIC CTI BioPharma $5.28 / -0.03 (-0.56%) CTI BioPharma announced a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options CTIC CTI BioPharma $5.28 / -0.03 (-0.56%) 04/14/22 CTI BioPharma's Vonjo included in NCCN Myeloproliferative Neoplasm guidelines 02/28/22 CTI BioPharma announces FDA accelerated approval of VONJO 12/13/21 CTI BioPharma presents data from pacritinib program at ASH 11/30/21 CTI BioPharma announces extension of FDA review period for pacritinib NDA CTIC CTI BioPharma $5.28 / -0.03 (-0.56%) 04/14/22 Stifel Stifel reiterates Buy on CTI BioPharma following new treatment guidelines 03/01/22 Brookline CTI BioPharma price target raised to $12 from $7.20 at Brookline 12/01/21 Lake Street CTI BioPharma delay creates buying opportunity, says Lake Street 10/04/21 Lake Street CTI BioPharma should be bought on weakness after PRE-VENT miss, says Lake Street CTIC CTI BioPharma $5.28 / -0.03 (-0.56%) 05/12/22 CTI BioPharma reports Q1 EPS (23c), consensus (41c) 03/31/22 CTI BioPharma reports Q4 EPS (38c), consensus (28c) CTIC CTI BioPharma $5.28 / -0.03 (-0.56%) 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 04/01/22 What You Missed On Wall Street On Friday 04/01/22 What You Missed On Wall Street This Morning 06/01/22 CTI BioPharma Corp. CTIC CTI BioPharma $5.28 / -0.03 (-0.56%) 05/12/22 CTI BioPharma options imply 10.5% move in share price post-earnings 04/18/22 Unusually active option classes on open April 18th 03/31/22 CTI BioPharma options imply 5.3% move in share price post-earnings 03/24/22 CTI BioPharma options imply 7.9% move in share price post-earnings
Hot Stocks	Cue Biopharma to present interim data on CUE-101 in head and neck cancer » 18:17 05/26/22 05/26 18:17 05/26/22 18:17 CUE Cue Biopharma $3.58 / -0.075 (-2.05%) Cue Biopharma will give a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events CUE Cue Biopharma $3.58 / -0.075 (-2.05%) 05/25/22 Cue Biopharma director buys $711.7K in common stock 05/11/22 Cue Biopharma receives FDA acceptance of IND application for CUE-102 04/04/22 Cue Biopharma director Fletcher acquires 735,000 common shares 03/02/22 Cue Biopharma to present updated overview of immuno-STAT platform CUE Cue Biopharma $3.58 / -0.075 (-2.05%) 03/23/22 JMP Securities Cue Biopharma price target lowered to $15 from $30 at JMP Securities 03/21/22 Oppenheimer Cue Biopharma price target lowered to $26 from $32 at Oppenheimer 03/18/22 Craig-Hallum Nektar failure 'not necessarily' a read through to Cue, says Craig-Hallum 01/03/22 Craig-Hallum Craig-Hallum bullish on Cue Biopharma, initiates with a Buy CUE Cue Biopharma $3.58 / -0.075 (-2.05%) 05/10/22 Cue Biopharma reports Q1 EPS (44c), consensus (43c) 06/09/22 Cue Biopharma Inc.
Hot Stocks	Ipsen's Cabometyx shows 'encouraging' efficacy results in different tumor types » 18:15 05/26/22 05/26 18:15 05/26/22 18:15 IPSEY Ipsen $25.81 / + (+0.00%) Ipsen announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly IPSEY Ipsen $25.81 / + (+0.00%) 05/03/22 Ipsen announces EC approval for Cabometyx as DTC monotherapy 03/25/22 Ipsen receives CHMP recommendation for Cabometyx approval 03/16/22 Ipsen to invest in new electronic autoinjector 02/15/22 Ipsen announces two-year follow-up data from CheckMate -9ER trial IPSEY Ipsen $25.81 / + (+0.00%) 04/29/22 Societe Generale Ipsen price target raised to EUR 120 from EUR 112 at Societe Generale 04/28/22 JPMorgan Ipsen price target raised to EUR 91 from EUR 88 at JPMorgan 04/27/22 Bryan Garnier Ipsen downgraded to Neutral from Buy at Bryan Garnier 04/14/22 Barclays Ipsen price target raised to EUR 95 from EUR 88 at Barclays IPSEY Ipsen $25.81 / + (+0.00%) 12/17/21 Wall Street in Fives - Must Read Lists for Friday 12/17/21 Wall Street in Fives - Must Read Lists at Midday

Events

Earnings calls, analyst events, roadshows and more

FANH
Today at 21:00

Fanhua - FANH Conference Calls
LIZI
Today at 21:00

Lizhi - LIZI Conference Calls
CWBC
Today at 21:30

Community West Bancshares Firm Sponsored Meetings

4015 Via Laguna, Santa Barbara, CA
Tomorrow at 00:00

Annual Neuro & Ophthalmology Virtual Investor Conference Conferences

Virtual Conference
Tomorrow at 00:00

TechNet Conference Asia Pacific 2022 Conferences

Virtual Conference
CYRX
Tomorrow at 00:00

Cryoport Firm Sponsored Meetings

Irvine, CA
IART
Tomorrow at 00:00

Integra LifeSciences Firm Sponsored Meetings

Los Angeles, CA
SABR
Tomorrow at 00:00

Sabre Firm Sponsored Meetings

West Coast
EXPO
Tomorrow at 00:00

Exponent Firm Sponsored Meetings

Chicago, IL
Tomorrow at 00:00

Metals & Mining Industry Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	KDNY X KDNY Chinook Therapeutics Spot Secondary Managers: SVB Leerink, Cantor Fitzgerald, William Blair & Wedbush Priced at: $14.00 6.429M Shares
Wed	ADC X ADC Agree Realty Spot Secondary Managers: Citi & Wells Fargo Priced at: $68.65 5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	ACB X ACB Aurora Cannabis Spot Secondary Managers: Canaccord & BMO Capital Priced at: $2.45 51.1M Shares
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	CLIR X CLIR ClearSign Combustion Spot Secondary Managers: Newbridge Securities $1.31
Fri	No deals

View All Syndicate Announcements »

Southwest says reducing Q1 capacity

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access